NCT05853575 2026-02-17Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Mirati Therapeutics Inc.Phase 2 Recruiting200 enrolled
NCT04685135 2025-01-22KRYSTAL-12Mirati Therapeutics Inc.Phase 3 Active not recruiting453 enrolled 20 charts
NCT04975256 2024-12-16Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)Mirati Therapeutics Inc.Phase 1 Terminated7 enrolled